MedTrace Logo

Utility of Presepsin in Children Sepsis

NCT02643121 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-01-01

No results posted yet for this study

Summary

Presepsin (formerly CD14), is a glycoprotein receptor occurring at the surface of monocytes/macrophages. CD14 binds to lipopolysaccharide (LPS) complexes and LPS binding protein (LPB), which triggers the activation of toll-like receptor 4 (TLR4), resulting in the production of numerous pro-inflammatory cytokines. Following Presepsin activation by bacterial products, the CD14 complex is released in the circulation as its soluble form (sCD14), which in turn is cleaved by a plasma protease to generate a sCD14 fragment called sCD14-subtype (sCD14- ST). Plasma levels of sCD14 can be measured using an automated chemo-luminescent assay (PATHFAST).

Conditions

  • Sepsis Syndrome

Interventions

OTHER

therapy sepsis

Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage

Sponsors & Collaborators

  • Brno University Hospital

    lead OTHER

Principal Investigators

  • Jiří Žurek, M.D., Ph.D. · Department of Anesthesia and Intensive Care, University Children´s Hospital

Eligibility

Min Age
1 Month
Max Age
216 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-12-31
Completion
2017-01-31

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02643121 on ClinicalTrials.gov